Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Karyopharm Therapeutics Inc Market Cap
From what 11 stock analysts predict, the share price for Karyopharm Therapeutics Inc (KPTI) might increase by 473.68% in the next year. This is based on a 12-month average estimation for KPTI. Price targets go from $2 to $7. The majority of stock analysts believe KPTI is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 11 Wall Street analysts have assignedKPTI 10 buy ratings, 0 hold ratings, and 1 sell ratings. This means that analysts expect Karyopharm Therapeutics Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on KPTI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of KPTI.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Edward White HC Wainwright & Co. | Buy | $7 | Reiterates | Aug 7, 2024 |
| Mitch Collett Baird | Outperform | $5 | Maintains | Aug 7, 2024 |
| Brian Abrahams RBC Capital | Outperform | $3 | Reiterates | Aug 7, 2024 |
| Edward White HC Wainwright & Co. | Buy | $7 | Maintains | Jun 28, 2024 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Jun 3, 2024 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | May 9, 2024 |
| Edward White HC Wainwright & Co. | Buy | $8 | Maintains | Mar 1, 2024 |
| Christopher Raymond Piper Sandler | Overweight | $5 | Maintains | Nov 3, 2023 |
| Brian Abrahams RBC Capital | Outperform | $3 | Maintains | Nov 3, 2023 |
| Michael Ulz Morgan Stanley | Equal-Weight | $4 | Maintains | Aug 7, 2023 |
| Edward White HC Wainwright & Co. | Buy | $10 | Reiterates | Aug 3, 2023 |
| Brian Abrahams RBC Capital | Outperform | $4 | Maintains | Aug 3, 2023 |
| Christopher Raymond Piper Sandler | Overweight | $7 | Maintains | Aug 3, 2023 |
| Edward White HC Wainwright & Co. | Buy | $10 | Reiterates | Jul 26, 2023 |
| David Nierengarten Wedbush | Neutral | $4 | Maintains | Jul 26, 2023 |
| Edward White HC Wainwright & Co. | Buy | $10 | Reiterates | Jul 18, 2023 |
| Edward White HC Wainwright & Co. | Buy | $10 | Maintains | May 5, 2023 |
| Mitch Collett Baird | Outperform | $10 | Maintains | May 5, 2023 |
| Brian Abrahams RBC Capital | Outperform | $5 | Maintains | May 5, 2023 |
| Edward White HC Wainwright & Co. | Buy | $16 | Reiterates | Apr 19, 2023 |
When did it IPO
2013
Staff Count
325
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Richard A. Paulson M.B.A.
Market Cap
$99.7M
In 2023, KPTI generated $146.0M in revenue, which was a decrease of -7.03% from the previous year. This can be seen as a signal that KPTI's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
